Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered drug target discovery, has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Investors can access the call via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through Compugen's website. A replay will be available on the website after the live event.
Compugen (NASDAQ: CGEN), un'azienda in fase clinica specializzata nell'immunoterapia oncologica e nella scoperta di target farmacologici supportata da AI/ML, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per mercoledì 6 agosto 2025, prima dell'apertura dei mercati statunitensi.
L'azienda terrà una conference call e una webcast alle 8:30 AM ET per discutere i risultati e fornire un aggiornamento aziendale. Gli investitori potranno partecipare alla chiamata tramite telefono (USA: 1-866-744-5399, Internazionale: +972-3-918-0644) o attraverso il sito web di Compugen. Una registrazione sarà disponibile sul sito dopo l'evento live.
Compugen (NASDAQ: CGEN), una empresa en etapa clínica especializada en inmunoterapia contra el cáncer y en el descubrimiento de objetivos farmacológicos impulsado por IA/ML, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el miércoles 6 de agosto de 2025, antes de la apertura de los mercados en EE.UU.
La compañía realizará una llamada conferencia y una transmisión web a las 8:30 AM ET para discutir los resultados y brindar una actualización corporativa. Los inversores podrán acceder a la llamada por teléfono (EE.UU.: 1-866-744-5399, Internacional: +972-3-918-0644) o a través del sitio web de Compugen. Una repetición estará disponible en el sitio después del evento en vivo.
Compugen (NASDAQ: CGEN)는 AI/ML 기반 약물 타겟 발굴을 전문으로 하는 임상 단계 암 면역치료 회사로, 2025년 2분기 재무 결과를 2025년 8월 6일 수요일 미국 시장 개장 전 발표할 예정입니다.
회사는 동부 표준시 기준 오전 8시 30분에 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 진행합니다. 투자자들은 전화(미국: 1-866-744-5399, 국제: +972-3-918-0644) 또는 Compugen 웹사이트를 통해 참여할 수 있습니다. 생중계 후 웹사이트에서 다시보기를 이용할 수 있습니다.
Compugen (NASDAQ : CGEN), une société en phase clinique spécialisée dans l'immunothérapie du cancer et la découverte de cibles médicamenteuses assistée par IA/ML, a prévu la publication de ses résultats financiers du deuxième trimestre 2025 pour le mercredi 6 août 2025, avant l'ouverture des marchés américains.
La société organisera une conférence téléphonique et une webdiffusion à 8h30 ET pour discuter des résultats et fournir une mise à jour d'entreprise. Les investisseurs pourront accéder à l'appel par téléphone (États-Unis : 1-866-744-5399, International : +972-3-918-0644) ou via le site web de Compugen. Une rediffusion sera disponible sur le site après l'événement en direct.
Compugen (NASDAQ: CGEN), ein klinisch fortgeschrittenes Krebsimmuntherapie-Unternehmen, das sich auf die Entdeckung von Arzneimittelzielen mit KI/ML spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Mittwoch, den 6. August 2025, vor der Öffnung der US-Märkte geplant.
Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über Telefon (USA: 1-866-744-5399, International: +972-3-918-0644) oder über die Website von Compugen teilnehmen. Eine Aufzeichnung wird nach der Live-Veranstaltung auf der Website verfügbar sein.
- None.
- None.
HOLON,
To access the live conference call by telephone, please dial 1-866-744-5399 from the
Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2025-results-on-wednesday-august-6-2025-302511823.html
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) release Q2 2025 earnings?
How can I access Compugen's Q2 2025 earnings call?
Will there be a replay available of Compugen's Q2 2025 earnings call?
What type of company is Compugen (CGEN)?
